Hyderabad: Bharat Biotech at Genome Valley in Shamirpet on the outskirts of the city, on Saturday said that they are humbled by the visit of Prime Minister Narendra Modi to the manufacturing facility.
Bharat Biotech, a leader in pandemic vaccines, also said we are truly honoured by this recognition.
Mr Modi’s visit serves as a great inspiration to our team, and further reinforces our commitment towards scientific discovery, solving public health issues, and the nation’s fight against COVID-19, Bharat Biotech said in a release here.
COVAXIN
India’s first indigenous vaccine with the Phase 3 clinical trial underway, is the first, largest, and the only efficacy trial in the developing world, involving a large number of volunteers across 25 sites.
The COVAXIN phase III trial is being conducted across India in 26,000 participants. The vaccine will be produced in the only-of-its-kind Biosafety Level 3 production facility in the world.
We take this opportunity to thank the Government of India, Regulators, our vaccine development partners, medical fraternity, medical investigators including hospitals for their relentless assistance and cooperation in the development of vaccines, also phase 3 clinical trials for COVAXIN, Hyderabad-based vaccine maker said.
